Payment overview · 2025
General Payments
$36,482.71
68 reported records · 11 companies
Healthcare provider profile · identity verified
Michael Ingram, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · BAY CITY, MI · NPI 1295767283
Verified facts
What the public records show
CMS Open Payments records show Michael Ingram, MD received $36,482.71 in general payments during 2025 across 68 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 57.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Ingrezza, Rexulti, Trintellix.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Auvelity by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Spravato by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20,778.21 | 57.0% | 24 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14,086.24 | 38.6% | 19 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $1,132.04 | 3.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $210.95 | 0.6% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $96.50 | 0.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $70.69 | 0.2% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $31.87 | 0.1% | 2 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $25.07 | 0.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.97 | 0.1% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $17.94 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.23 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,460.00 | 12 |
| Consulting Fee | $7,496.25 | 3 |
| Travel and Lodging | $4,100.26 | 13 |
| Food and Beverage | $1,426.20 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20,778.21 | 24 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $14,086.24 | 19 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $13,930.91 | 17 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,113.75 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $210.95 | 13 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $167.19 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $31.87 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| REJOYN Normalized: rejoyn |
Device | Otsuka Pharmaceutical Development & Commercialization, Inc. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | SPRAVATO open payments reported associated product |
CMS Open Payments — General Payments 43813 supporting records · 17025 recipient NPIs · example record 1174223254 |
Spravato · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 214 | 55 |
| Buspirone Hcl | Buspirone Hcl | 196 | 43 |
| Clonazepam | Clonazepam | 167 | 39 |
| Lamotrigine | Lamotrigine | 132 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 27 |
| Bupropion Xl | Bupropion Hcl | 96 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 80 | 24 |
| Olanzapine | Olanzapine | 78 | 17 |
| Aripiprazole | Aripiprazole | 75 | 19 |
| Sertraline Hcl | Sertraline Hcl | 66 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 14 |
| Vraylar | Cariprazine Hcl | 58 | suppressed |
| Mirtazapine | Mirtazapine | 53 | 14 |
| Austedo | Deutetrabenazine | 52 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 50 | suppressed |
| Risperidone | Risperidone | 48 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 46 | 12 |
| Paliperidone Er | Paliperidone | 45 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 42 | 12 |
| Oxcarbazepine | Oxcarbazepine | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 11 |
| Lithium Carbonate | Lithium Carbonate | 36 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 35 | suppressed |
| Clozapine | Clozapine | 35 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Rexulti | Brexpiprazole | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 25 | suppressed |
| Austedo Xr | Deutetrabenazine | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Risperidone Odt | Risperidone | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 20 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 18 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Gabapentin | Gabapentin | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Disulfiram | Disulfiram | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Emsam | Selegiline | 11 | suppressed |
| Spravato | Esketamine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36,482.71 · 68 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY ASIMTUFII, Auvelity, CAPLYTA, COBENFY, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, REJOYN, REXULTI, SUBLOCADE, TRINTELLIX | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Axsome Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error